Analysis of the Therapeutic and Clinical Profile of Cannabinoid Treatments: A Real-World Study

Enrolling by invitation

Conditions studied: Chronic Pain, Depression Disorders, Anxiety Disorders, Quality of Life, Cannabidiol Effects, Cannabinoids

In brief

What is the purpose of this study? The use of medicinal cannabis has grown significantly in Brazil. However, because many patients use these products through "compassionate use" (when traditional treatments haven't worked), there is still a lack of large-scale data on how these treatments perform in daily life. This study, called CANAREAL, aims to track patients across Brazil to understand if cannabis-based products are truly effective and safe for treating various conditions, such as chronic pain, anxiety, and depression. How will the study work? This is an observational study, which means the researchers will not provide the medication or change the treatment prescribed by the patient's doctor. Instead, we will simply "follow" the patient's journey for 6 months. What will participants be asked to do? Participants will complete online questionnaires at different stages of their treatment. These tools will measure: Quality of Life: How the treatment affects daily well-being. Clinical Evolution: Changes in pain levels, anxiety, and depression symptoms. Safety: Whether the patient experiences any side effects (adverse events). Why is this study important? Unlike controlled laboratory tests, this "Real-World Study" captures the reality of diverse patients with different backgrounds and health needs. The information gathered will help doctors, patients, and health authorities in Brazil better understand the benefits and risks of cannabinoid therapy, leading to safer and more informed medical decisions in the future.

Key facts

Study ID

NCT07362407

Run by

Santa Catarina Federal University

People needed

384

Starts

2026-03-01

Expected to finish

2026-12-01

Last updated by the study team

2026-03-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged 18 years or older.
• Residents of Brazil.
• Patients who have a valid medical prescription for cannabis-based products.
• Patients who are either starting a new treatment or are already using cannabinoid products under the ANVISA RDC 660/22 or RDC 327/19 regulations.
• Capability to understand and sign the Informed Consent Form (ICF).
• Access to a smartphone or computer with internet to complete the digital follow-up questionnaires.

You may not qualify if…

• Patients who do not agree to the terms of the Informed Consent Form (ICF).
• Patients who fail to complete the initial (Baseline/T0) sociodemographic and clinical questionnaires.
• Inability to communicate.

Where it is running

• Universidade Federal de Santa Catarina (UFSC), Centro de Ciências Biológicas (CCB), Campus Universitário, Trindade, Florianópolis - SC. — Florianópolis, Santa Catarina, Brazil

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.